Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $53.54M fell 6.6% year over year, behind the +25.7% change in trailing-twelve-month revenue. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $171.07M (-27.6%) for the fiscal year ending Dec 2026, a slowdown from the +47.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$53.54M-7.1% QoQ
Last fiscal yearDec 2025
$236.2M+47.5% YoY
LTMMar 2026
$232.4M+25.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.6%-21.8%-15.2 pp
1 year+47.5%-27.6%-75.0 pp
3-year CAGR-6.9%-23.4%-16.5 pp
5-year CAGR-9.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
236.2M USD
Year-over-year change
+47.5%
4-year CAGR
+2.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 revenue of $232.4M is the 2nd highest of the 10 companies compared; the peer median is $57.94M.
  • Its year-over-year change of +25.7% is the 4th highest of 7, against a peer median of -3.9%.
  • Over three fiscal years its annual growth of -6.9% compares with a peer median of +76.8%.
AKBA Competitors Peer median
Revenue for AKBA and competitors
Company Period LTM YoY 3-year CAGR
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$299.77M +47.6%+34.8%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$232.4M +25.7%-6.9%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$122.29M +201.3%+118.8%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$115.91M ——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$88.24M +383560.9%+200.9%
PRTAProthena Corporation plcLTM Mar 2026$57.94M -58.0%-43.6%
GOSSGossamer Bio, Inc.LTM Mar 2026$55.54M -55.4%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$0 ——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 ——
CMPXCompass Therapeutics, Inc.LTM Mar 2026$0 -100.0%—
Peer median (excluding AKBA) $57.94M-3.9%+76.8%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.